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6
7 Use of the acronym “NPS” has unquestionably become more common in recent years. 
8 Policymakers, medical personnel, toxicologists, law enforcement officials, social workers, and 
9 journalists, have gradually become familiar with the phenomenon of the New Psychoactive 
10 Substances (NPS). The initial warnings about NPS use and abuse were issued in 2009, and NPS 
11 progressively became a global issue, with over 100 countries and regions throughout the world 
12 having reported the emergence of NPS. In recent years, the consumption of NPS has proliferated 
13 at an unprecedented rate and poses a significant risk to the public health and a challenge to 
14 national and international drug policies 1. The frequent emergence of new NPS on the black market 
15 (until recently) prevented affordable and timely analytical procedures; consequently, potential laws 
16 forbidding possession or use in specific contexts (e.g., driving) were not enforceable. In practice, 
17 NPS have not been routinely screened and they are still commonly used without legal 
18 consequences. Only recently, laboratories have begun to offer screening and confirmation analysis 
19 for NPS in the context of workplace drug testing, driving re-licensing, roadside control, and 
20 withdrawal programs 2,3. Still, the application of these analytical methods remains somewhat 
21 sporadic and confined to highly specialized laboratories. Furthermore, these sophisticated 
22 analyses involve considerable costs, rarely affordable by clients.
23 A series of new factors may modify this unfavorable analytical situation for NPS screening in 
24 forthcoming years, especially in the context of workplace drug testing (WDT). First, several 
25 countries have banned entire classes of NPS, irrespective of their specific chemical structure 4. 
26 Secondly, among the large variety of NPS, some are proven to have “desirable” pharmacological 
27 effects, while others are more likely to disappear because of their unpleasant side-effects 5-7. Third, 
28 pharmacokinetic studies progressively provide information about the various NPS metabolic 
29 pathways and the target analytes to look for, in different biological matrices. Lastly, and most 
30 importantly, recent technological developments may make screening analysis for NPS more 
31 affordable and effective. For example, the modern UHPLC-MS/MS instrumentation allows the 
32 detection of large NPS panels within a single analytical run, covering different classes of target 
33 analytes due to their compatibility with unspecific (i.e., general) sample extraction procedures 8-10. 
34 Further prospect gaining increasing interest among forensic toxicologists is anticipated by the 
35 development of non-targeted approaches allowed by modern UHPLC-HRMS instrumentation 11-13. 
36 Screening non-targeted analysis for NPS is also taking advantage from the significant 
37 advancement of other new technologies, such as the assays for the detection of synthetic 
38 cannabinoid receptor agonists (SCRAs) based on interactions of the compounds with CB1 and 
39 CB2 receptors 14. The practical consequence of all these new elements is that more stable and 
40 revisable wide-ranging analytical procedures are progressively developed and made available to 
41 detect the intake of NPS and to screen biological samples for the presence of NPS without 
42 knowing their exact chemical structure. Eventually, the occurrence of false negative results is likely 
43 to decrease considerably in forthcoming years. More importantly, the cost of analysis will decrease, 
44 which is a particularly important factor in the context of WDT.
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45 Testing in the workplace is a complex topic as it is not often directly regulated by supranational or 
46 national law. Only few countries report legislation that clearly and specifically address the issue of 
47 drug testing in the workplace. Among all countries, divergent approaches are evident, regarding 
48 the timing of testing, the location, the frequency, the subjects, and the type of specimen(s) to be 
49 tested, the panel(s) of drugs, and the guarantees concerning individual privacy and legal 
50 consequences. Random and pre-employment testing are the most common strategies adopted in 
51 WDT, generally based on urine or oral fluid analysis. While the latter would simply require a 
52 comprehensive screening of NPS parent drugs, the former is more complex as it requires 
53 knowledge and inclusion of several metabolites. It is certainly challenging to identify which 
54 legislative approach each government should adopt. Generic legislations have aimed to control 
55 both individual NPS and other have aimed to ban any group of substances with structural 
56 similarities 15,16. Unfortunately, WDT is often neglected in many countries where a specific 
57 legislation has not been enacted. Italy is a rare case where drug tests (although not for NPS) are 
58 mandatory for certain jobs entailing safety risks to third parties, while on the other hand are 
59 prohibited under different conditions. In other European countries, employers and companies are 
60 allowed to activate a WDT program under specific circumstances (e.g., if stated in the contract) or 
61 at discretion of an occupational doctor. 
62 In WDT, the most prevalent classes of NPS should be tested (e.g., synthetic cathinones, synthetic 
63 cannabinoids, fentanyl and its analogs), selecting the most common molecules within each class. 
64 However, analytical laboratories must constantly update their methods and keep pace with the 
65 introduction of new compounds into the black market. Nevertheless, several international alert and 
66 warning systems, as well scientific reports and publications, can certainly assist this demanding 
67 process. While the exclusion of NPS from WDT certainly appears to influence their diffusion, on the 
68 other hand, we believe that new and general directives for NPS testing are needed to prevent their 
69 use and ensure health and safety of workers. Nevertheless, these directives should respect the EU 
70 legislation on privacy and exclude unjustified intrusion into the employees’ lifestyle. In this 
71 perspective, a preliminary step to foster NPS testing in the workplace context was attempted by the 
72 European Workplace Drug Testing Society. In hair-testing guidelines published in 2015, it was 
73 recommended that “WDT protocols should consider this investigation when the laboratory is 
74 offering screening and confirmation for NPS” 17. If implemented, workplace NPS testing would 
75 likely enjoy the dual benefit of the deterrent effect on the workforce and the phenomenon 
76 monitoring at various times and in different countries, eventually supporting the employee and 
77 providing pathways to treatment. Furthermore, an overall assessment of NPS diffusion and trends 
78 would become possible, allowing clear knowledge of their consumption within specific populations 
79 and the potential connection between their intake and, for example, occupational accidents.
80 Two possible scenarios are likely to account for the intake of NPS by individuals, and specifically 
81 those involved in regular (urine) testing, for instance, within the procedures for driver’s license 
82 recovery or in WDT. The first scenario suggests that certain classes of drug consumers will 
83 substitute traditional cannabis products or “old” stimulants with new synthetic substances, allowing 
84 them to avoid judicial sanctions 18,19. The replacement of “old” drugs with NPS is attractive to some 
85 users as long as these new classes of substances are not routinely screened, especially in those 
86 countries where possession and use of illegal substances is more severely punished. The second 
87 motivation often reported for NPS use is their novelty: new products have become available to the 
88 public, often stimulating curiosity to test and compare different effects and sensations.
89 A different but perhaps equally worrying situation is represented by the unintentional intake of NPS 
90 (as adulterants), to whom ecstasy users (for example) are at particularly high risk for unknown 
91 exposure. Forensic investigations based either on drug seizures or alternative toxicological 
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92 approaches (e.g., oral fluid, hair analysis, drug checking services), have shown that tablets sold as 
93 “ecstasy” (or more recently, “Molly” in the US) can contain various substances other than MDMA, 
94 including a variety of NPS 20-27, which can cause unpredictable and often unknown adverse effects. 
95 Nevertheless, the adulteration or replacement of “traditional” drugs with NPS is not limited to 
96 ecstasy. In both North America and Europe, novel synthetic opioids (NSO) are often sold as 
97 purported heroin (and in some cases also as cocaine) to unsuspecting drug users 28-31. In 
98 particular, fentanyl analogs have been linked to a large and rising number of overdose deaths 
99 among opiate and opioid users 32. 
100 Nevertheless, interpretation of a positive finding would need caution, before any sanction is 
101 imposed to the tested employee. The risk of false positive results certainly represents a key issue 
102 before a decision is taken about the generalized extension of NPS testing. Some laboratories have 
103 set the limit of detection as the minimum criterion to establish use of a new drug, but this can only 
104 prove the “exposure” to a new substance. This approach has to be considered improper and 
105 preliminary, since few studies have explored criteria to differentiate 1) between occasional and 
106 regular intake, 2) between occasional intake and passive exposure, or 3) external contamination. 
107 Moreover, the mere detection f a drug in urine or hair is not useful in proving the subject as being 
108 under the drug’s effect nor to assess the worker’s inability to carry out his or her job. Aside from the 
109 limit of detection, which is also highly dependent on the method’s sensitivity, different cut-offs 
110 based on a large population of consumers or controlled studies should be proposed. In addition, 
111 distinction between recent (i.e., possibly causing impairment at the workplace), chronic (i.e., hinting 
112 a possible addiction state), and occasional (i.e., recreational) use should be considered, with 
113 respect to both analysis results and their interpretation. In this context, an experienced toxicologist 
114 should evaluate these cases with caution, and the scientific societies should play a fundamental 
115 role in addressing future drug laws and policies, suggesting cut-offs, specimens to be tested, and 
116 criteria to differentiate between past use, chronic use, or impairment at the workplace.
117 Inclusion strategies of NPS into WDT have pros and cons that should be carefully considered, and 
118 current strategies may require revision and possibly updates in forthcoming years, but it is 
119 important to engage in debate about the ultimate objectives of NPS testing and the balance 
120 between costs and benefits arising from their screening. The Italian WDT experience for traditional 
121 drugs of abuse has shown very low prevalence of positive results, possibly because the mandatory 
122 “surprise sample collection” is rarely respected while the short detection window of consumed 
123 substances in the urine matrix allows even habitual consumers to keep off from drugs just few days 
124 before control 33. The latter example proves that even adequate analytical procedures turn out to 
125 be ineffective if the whole procedure from sample collection to data reporting is not under control. 
126 Transposing this concept into NPS testing, it is clear that systematic monitoring of the data arising 
127 from an extended WDT program would be highly recommended, together with the assessment of 
128 its effectiveness. Examples of direct and indirect parameters useful for a comprehensive evaluation 
129 of NPS testing are the reduction rate of workplace accidents and prevalence of detection of NPS 
130 use in the workforce. The obtained data would certainly assist the implementation of more general 
131 policies of social and health interest, which every government should pursue.
132 Summarizing, caution is certainly recommended to avoid the indiscriminate criminalization of NPS 
133 use 34,35. Some cases may require careful result interpretation from the occupational doctor, who 
134 may also request opinions from clinical and/or forensic toxicologists, or pharmacologists, especially 
135 in cases where alleged NPS/NSO are licitly taken. The situation is well-illustrated by several 
136 synthetic opioids (e.g., fentanyl and oxycodone), which can be prescribed for clinical purposes 
137 and/or misused (e.g., because of an existing state of addiction). Another example of criticism is 
138 given by the structure-based legislation: since an extremely wide range of new molecules with 
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139 similar structures can be synthetized, it is realistic to foresee that, at some point, an overlapping 
140 between the urinary metabolites of licit (i.e., medications) and illicit (i.e., unauthorized drugs) 
141 substances will occur. In this context, the recent use of medications possibly containing NPS/NSO 
142 or their metabolites will have to be disclosed before sample collection and possibly supported by a 
143 written prescription. Appropriate confirmation analysis on the collected biological sample will 
144 therefore be needed to confirm the exact chemical structure of the taken substance.
145 Irrespective of the necessary caution, it is increasingly evident that many of the new substances 
146 available in recent years may represent a serious threat to employee health and the maintenance 
147 of a safe workplace. We believe that prevention of drug use-related occupational accidents must 
148 be a prerogative for all governments, and this would be facilitated by an effective and 
149 comprehensive testing program. As a safeguard to all subjects involved in the process, efforts 
150 have to be addressed to identify and promote best practices for collection, analysis and 
151 interpretation of drug tests. Guidelines are already available 17,36-38 and many companies and 
152 laboratories performing the WDT worldwide are already complying with them. More is to follow, 
153 especially with regard to NPS/NSO, in order to make everyone, from the employer to the sample 
154 collector, increasingly aware of their accountability in a decision with serious consequences.
155
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